Business
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing
MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. ( TSX:MBX)(OTCQ...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products (\"QAPs™\") and its availability at commercial scale for test manufacturers.This is the first commercial product to emerge from the development program announced in January 2025, whereby Microbix committed to extend its capabilities into recombinant (i.e., synthetic) antigen production to complement its longstanding expertise in native antigen production. This internally-made recombinant antigen has been developed, manufactured at commercial scale, and fully validated. Accordingly, it is now being used in Microbix's QAPs to support clinical laboratory proficiency testing or external quality assessment programs (\"PT\" or \"EQA\"), and is being incorporated into PROCEEDx® (RUO) and REDx® (IVD) branded QAPs used to support ongoing quality management of clinical laboratories or other testing sites.Microbix has 40 years of expertise in the technically-challenging manufacturing of native viral antigens, which requires culturing of mammalian host cells, the addition and growth of target viruses in those cells, and, finally, the extraction, purification, and inactivation of high-quality components for infectious-disease tests in commercial quantities. That expertise is now joined by a newly-demonstrated ability to make recombinant/synthetic antigens, which when appropriately designed and manufactured can substitute for native antigens in suitable contexts. Additionally, in-house recombinant production improves Microbix's supply-chain security and enables better control of costs, which is intended to help Microbix remain a leading supplier of QAPs to clients in the PT/EQA, test-manufacturing, and clinical laboratory fields.Since its emergence as a novel pandemic in 2019, SARS-CoV-2 has become endemic worldwide. Accordingly, there is an ongoing market in antigen-based testing for this virus. Microbix's SARS-CoV-2 antigen QAPs support quality assessment needs related to such testing...